載入...
Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report
BACKGROUND: Dabigatran is a direct thrombin inhibitor with a favorable effectiveness and safety profile when compared to vitamin K antagonists, both in randomized trials and real world registries of atrial fibrillation patients. Yet, physicians’ fear of high bleeding risk scenarios in daily clinical...
Na minha lista:
| 發表在: | Thromb J |
|---|---|
| Main Authors: | , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5583973/ https://ncbi.nlm.nih.gov/pubmed/28878572 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12959-017-0147-z |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|